Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 1 of 1 entries
Sorted by: Best Match Show Resources per page
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.

Contemporary oncology (Poznan, Poland)

Krawczyk PA, Kowalski DM.
PMID: 24876815
Contemp Oncol (Pozn). 2014;18(1):7-16. doi: 10.5114/wo.2013.38566. Epub 2013 Nov 14.

Efficacy of monoclonal anti-EGFR antibodies (cetuximab, panitumumab) used in combination with chemotherapy or alone has been demonstrated in clinical trials of patients with mCRC. Both drugs block signaling EGFR pathway in malignant cells (blocking ligand binding and EGFR dimerization)....

Cite
Krawczyk PA, Kowalski DM. Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemp Oncol (Pozn). 2013;18(1):7-16doi: 10.5114/wo.2013.38566.
Krawczyk, P. A., & Kowalski, D. M. (2014). Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemporary oncology (Poznan, Poland), 18(1), 7-16. https://doi.org/10.5114/wo.2013.38566
Krawczyk, Paweł Adam, and Kowalski, Dariusz M. "Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer." Contemporary oncology (Poznan, Poland) vol. 18,1 (2014): 7-16. doi: https://doi.org/10.5114/wo.2013.38566
Krawczyk PA, Kowalski DM. Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemp Oncol (Pozn). 2014;18(1):7-16. doi: 10.5114/wo.2013.38566. Epub 2013 Nov 14. PMID: 24876815; PMCID: PMC4037996.
Copy Download .nbib Format: NLM
Showing 1 to 1 of 1 entries